Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selegiline transdermal - Somerset Pharmaceuticals

Drug Profile

Selegiline transdermal - Somerset Pharmaceuticals

Alternative Names: Emsam

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Somerset Pharmaceuticals
  • Class Analgesics; Antidementias; Antidepressants; Antiparkinsonians; Phenethylamines; Small molecules
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Major depressive disorder
  • No development reported Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease

Most Recent Events

  • 29 May 2009 Selegiline is no longer licensed to Bristol-Myers Squibb in USA; Dey LP aquires marketing rights
  • 28 Jul 2008 Somerset Pharmaceuticals has become a wholly owned subsidiary of Mylan Inc.
  • 08 May 2008 Efficacy data from a post-hoc analysis in Depression presented at the 161st Annual Meeting of the American Psychiatric Association (APA-2008)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top